Scarica l'app Stockscreener
1.99
2.58%
0.05
Dopo l'orario di chiusura:
1.97
-0.02
-1.01%
Precedente Chiudi:
$1.94
Aprire:
$1.95
Volume 24 ore:
193.55K
Relative Volume:
0.16
Capitalizzazione di mercato:
$62.60M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-0.7158
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
-3.86%
1M Prestazione:
+9.94%
6M Prestazione:
+42.14%
1 anno Prestazione:
-75.12%
Intervallo 1D:
$1.9401
$2.01
Intervallo di 1 settimana:
$1.88
$2.175
Portata 52W:
$1.05
$8.74
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Confronta ACRV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.99 | 61.02M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Can Acrivon Therapeutics Inc. stock weather global recessionMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Is Acrivon Therapeutics Inc. stock attractive for hedge fundsBull Run & Fast Momentum Entry Tips - newser.com
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance
Why Acrivon Therapeutics Inc. stock is recommended by analystsJuly 2025 Closing Moves & Community Verified Trade Signals - newser.com
Will Acrivon Therapeutics Inc. stock split attract more investors2025 Top Decliners & Free Low Drawdown Momentum Trade Ideas - newser.com
What high frequency data says about Acrivon Therapeutics Inc.Weekly Gains Report & Fast Exit Strategy with Risk Control - newser.com
Will Acrivon Therapeutics Inc. rebound enough to break evenDip Buying & Free Reliable Trade Execution Plans - newser.com
Custom strategy builders for tracking Acrivon Therapeutics Inc.2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
Is Acrivon Therapeutics Inc. stock a contrarian buyWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com
Is Acrivon Therapeutics Inc. stock supported by strong cash flows2025 Market WrapUp & Precise Buy Zone Identification - newser.com
Will Acrivon Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Levels & Weekly High Momentum Picks - newser.com
Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications - TipRanks
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):